Green Alpha Advisors LLC Buys 3,174 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

Green Alpha Advisors LLC boosted its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 5.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,845 shares of the company’s stock after buying an additional 3,174 shares during the quarter. Green Alpha Advisors LLC owned approximately 0.09% of Editas Medicine worth $509,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of EDIT. State Street Corp raised its holdings in shares of Editas Medicine by 43.8% in the 2nd quarter. State Street Corp now owns 7,879,890 shares of the company’s stock valued at $93,219,000 after purchasing an additional 2,399,852 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Editas Medicine by 151.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,650,010 shares of the company’s stock valued at $14,635,000 after purchasing an additional 993,508 shares in the last quarter. BlackRock Inc. raised its stake in shares of Editas Medicine by 15.5% during the 1st quarter. BlackRock Inc. now owns 6,275,270 shares of the company’s stock worth $119,355,000 after acquiring an additional 841,894 shares in the last quarter. Pictet Asset Management SA raised its stake in shares of Editas Medicine by 325.0% during the 1st quarter. Pictet Asset Management SA now owns 1,056,973 shares of the company’s stock worth $7,663,000 after acquiring an additional 808,302 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Editas Medicine by 296.1% during the 1st quarter. Renaissance Technologies LLC now owns 903,400 shares of the company’s stock worth $17,183,000 after acquiring an additional 675,300 shares in the last quarter. Institutional investors own 76.61% of the company’s stock.

Insider Transactions at Editas Medicine

In other news, SVP Baisong Mei sold 4,317 shares of the business’s stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $8.80, for a total transaction of $37,989.60. Following the completion of the sale, the senior vice president now owns 72,055 shares of the company’s stock, valued at $634,084. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 5,263 shares of company stock valued at $46,111 over the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Chardan Capital reduced their price objective on shares of Editas Medicine from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday, August 2nd. Oppenheimer reiterated a “market perform” rating and set a $12.00 price objective on shares of Editas Medicine in a research note on Thursday, August 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $14.00 target price on shares of Editas Medicine in a research report on Wednesday. Raymond James raised shares of Editas Medicine from a “market perform” rating to an “outperform” rating and set a $17.00 target price on the stock in a research report on Monday, June 12th. Finally, StockNews.com began coverage on shares of Editas Medicine in a research report on Thursday, August 17th. They set a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $15.57.

Editas Medicine Price Performance

EDIT stock opened at $8.40 on Friday. The firm has a 50-day simple moving average of $8.81 and a 200-day simple moving average of $8.62. Editas Medicine, Inc. has a 52 week low of $6.33 and a 52 week high of $16.16.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Wednesday, August 2nd. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.20. The business had revenue of $2.89 million during the quarter, compared to analysts’ expectations of $4.17 million. Editas Medicine had a negative net margin of 1,065.39% and a negative return on equity of 55.14%. The company’s quarterly revenue was down 54.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.78) earnings per share. On average, analysts predict that Editas Medicine, Inc. will post -2.55 EPS for the current fiscal year.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.